Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Burroughs Wellcome Co. Begins U.S. Clinical Trial Program with


PR Newswire (02/28/95)

On Tuesday, Vertex Pharmaceuticals Inc. and Burroughs Wellcome Co. announced the commencement of a Phase I clinical trial for VX-478 in the United States. The trial is a dose escalation trial designed to test the tolerability, pharmacokinetics, and oral bioavailability of VX-478, an orally administered protease inhibitor for the treatment of HIV infection and AIDS that was designed by Vertex. The study is the first in an international clinical development program for VX-478 being undertaken by Burroughs Wellcome, Kissei Pharmaceutical Co., and Vertex. Burroughs Wellcome and Kissei will use the results of the trial to develop trials to determine the safety and anti-HIV efficacy of VX-478 alone and in combination with reverse transcriptase inhibitors. "The Burroughs Wellcome- sponsored clinical program and the Kissei studies planned for Japan are part of an effort that is both extensive and designed to generate data rapidly on VX-478," said Dr. Joshua Boger, President and CEO of Vertex. "We and our partners believe that the pharmaceutical attributes of VX-478 make it a very promising drug candidate for the treatment of AIDS and HIV infection."


Copyright © 1995 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in March 1, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.